Keywords
Dilated Cardiomyopathy
Cardiology
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the characteristics of Hypertrophic (HCM) and Dilated Cardiomyopathies (DCM). Literature review: Patients with hypertrophic or dilated cardiomyopathy may present from asymptomatic to severe impairment of daily activities, with important clinical manifestations such as dyspnea, chest pain, fatigue, peripheral edema, palpitations, arrhythmias and, in more severe cases, even sudden cardiac death. Cardiomyopathies are intrinsic heart diseases characterized by structural changes in the myocardium, with both genetic and acquired etiologies. The average prevalence of these conditions in the world population is 1:250 to 1:500 in adults, although the expression of the disease occurs more frequently in young people. These conditions affect cardiac contractility and hemodynamics, and depending on the extent of myocardial involvement, can severely impair patients' quality of life. Final considerations: Hypertrophic cardiomyopathy is characterized by an increase in the thickness of the left ventricle. Dilated cardiomyopathy is defined by left ventricular or biventricular dilation, with impaired ejection fraction. In this context, knowledge about such pathologies is essential in order to promote adequate diagnosis and therapy, providing quality of life for patients.
References
AKHTAR M, ELLIOTT PM. Risk Stratification for Sudden Cardiac Death in Non-Ischaemic Dilated Cardiomyopathy. Current Cardiology Reports, 2019; 21(12): 155.
ARGIRO A, et al. Sex-Related Differences in Genetic Cardiomyopathies. Journal of American Heart Association, 2022; 11: e024947.
BECKER MAJ, et al. The Prognostic Value of Late Gadolinium-Enhanced Cardiac Magnetic Resonance Imaging in Nonischemic Dilated Cardiomyopathy: A Review and Meta-Analysis. JACC: Cardiovascular Imaging, 2018; 11(9): 1274-1284.
BRAUNWALD E. Cardiomyopathies: An Overview. Circulation Research, 2017; 121: 711-721.
BRIELER J, et al. Cardiomyopathy: An Overview. Am Fam Physician, 2017; 96(10): 640-646.
COJAN-MINZAT BO, et al. Non-ischemic dilated cardiomyopathy and cardiac fibrosis. Heart Failure Review, 2021; (5): 1081-1101.
DYBRO AM, et al. Randomized Trial of Metoprolol in Patients with Obstructive Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2021; 78(25): 2505-2517.
ENZAN N, et al. The use of angiotensin II receptor blocker is associated with greater recovery of cardiac function than angiotensin-converting enzyme inhibitor in dilated cardiomyopathy. ESC Heart Failure, 2022; 9(2): 1175-1185.
GLUCKMAN TJ. Hypertrophic Cardiomyopathy: Diagnosis and Therapeutic Options. Am J Manag Care, 2021; 27(6): 111-117.
HABIB M, et al. Temporal Changes in Cardiac Morphology and Its Relationship with Clinical Characteristics and Outcomes in Patients with Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2022; 176: 125-131.
HALAND T, EDVARDSEN T. The role of echocardiography in management of hypertrophic cardiomyopathy. Journal of Echocardiography, 2020; 18: 77-85.
LONG C, et al. Sex Differences in Dilated Cardiomyopathy Prognosis. International Heart Journal, 2022; 63(1): 36-42.
MAISCH B, PANKUWEIT S. Inflammatory dilated cardiomyopathy. Herz Cardiovascular Diseases, 2020; 45: 221-229.
MARIAN AJ, BRAUNWALD E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circulation Research, 2017; 121(7): 749-770.
MARON BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2018; 379: 655-668.
MCKENNA WJ, et al. Classification, Epidemiology, and Global Burden of Cardiomyopathies. Circulation Research, 2017; 121: 722-730.
MCNALLY EM, MESTRONI L. Dilated cardiomyopathy: genetic determinants and mechanisms. Circulation Research, 2018; 121(7): 731-748.
MEDICAL MASTERCLASS, FIRTH J. Cardiology: hypertrophic cardiomyopathy. Royal College of Physicians, 2019; 19(1): 61-63.
MERLO M, et al. Evolving concepts in dilated cardiomyopathy. European Journal of Heart Failure, 2017; 20(2): 228-239.
ORPHANOU N, et al. Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments. Heart Failure Reviews, 2021; 27(4): 1173-1191.
PETERS S, et al. Familial Dilated Cardiomyopathy. Heart Lung Circulation, 2020; (4): 566-574.
RANJBARVAZIRI S, et al. Altered Cardiac Energetics na Mitochondrial Dysfunction in Hypertrophic Cardiomyopathy. Circulation, 2021; 144: 1714-1731.
REICHART D, et al. Dilated cardiomyopathy: from epidemiologic to genetic phenotypes. Journal of Internal Medicine, 2019; 286(4): 362-372.
ROMANO MMD. Ecocardiograma Guiando Tratamento Percutâneo de Cardiomiopatia Hipertrófica Obstrutiva: Navegar (em Águas Conhecidas) e preciso. Arquivo Brasileiro de Cardiologia, 2022; 118(5): 873-874.
SAROHI V, et al. A Comprehensive Outlook on Dilated Cardiomyopathy (DCM): State-Of-The-Art Developments with Special Emphasis on OMICS-Based Approaches. Journal of Cardiovascular Development and Disease, 2022; 9(6): 174.
SCHULTHEISS HP, et al. Dilated cardiomyopathy. Nature Reviews Disease Primers, 2019; 5(1): 32.
SINAGRA G, et al. Risk stratification in cardiomyopathy. European Journal of Preventive Cardiology, 2020; 27(2): 52-58.
TAYAL U, et al. Precision Phenotyping of Dilated Cardiomyopathy Using Multidimensional Data. American Journal of Cardiology, 2022; 79(22): 2219-2232.
YOUNG L, et al. Hypertrophic cardiomyopathy: A complex disease. Cleveland Clinic Journal of Medicine, 2018; 85 (5): 399-411.
ZEGKOS T, et al. Mitral regurgitation impact on left atrial myopathy in hypertrophic cardiomyopathy. Echocardiography, 2022; 39(6): 819-826.